Zacks: Analysts Expect Neuronetics Inc (NASDAQ:STIM) Will Announce Earnings of -$0.51 Per Share

Wall Street analysts forecast that Neuronetics Inc (NASDAQ:STIM) will post earnings per share (EPS) of ($0.51) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Neuronetics’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.54). Neuronetics posted earnings of ($0.39) per share during the same quarter last year, which would indicate a negative year over year growth rate of 30.8%. The business is scheduled to issue its next quarterly earnings results on Tuesday, August 4th.

According to Zacks, analysts expect that Neuronetics will report full-year earnings of ($1.73) per share for the current fiscal year, with EPS estimates ranging from ($1.74) to ($1.71). For the next year, analysts expect that the business will post earnings of ($0.81) per share, with EPS estimates ranging from ($1.23) to ($0.39). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Neuronetics.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.13). The company had revenue of $11.48 million for the quarter. Neuronetics had a negative net margin of 55.58% and a negative return on equity of 68.77%.

A number of analysts have recently weighed in on the company. Zacks Investment Research lowered Neuronetics from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. William Blair lowered Neuronetics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 5th. BTIG Research reissued a “buy” rating and set a $6.00 price objective on shares of Neuronetics in a research note on Tuesday, May 5th. Finally, Canaccord Genuity reissued a “buy” rating and set a $4.00 price objective on shares of Neuronetics in a research note on Wednesday, May 6th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $4.75.

Shares of NASDAQ:STIM traded down $0.05 during trading on Friday, reaching $1.83. 269,141 shares of the company traded hands, compared to its average volume of 1,348,409. The firm has a market capitalization of $34.27 million, a price-to-earnings ratio of -0.99 and a beta of 1.48. Neuronetics has a 52-week low of $1.25 and a 52-week high of $13.31. The company has a current ratio of 6.17, a quick ratio of 5.94 and a debt-to-equity ratio of 1.03. The business’s fifty day moving average is $1.97 and its 200-day moving average is $2.77.

A number of hedge funds have recently made changes to their positions in the stock. State Street Corp lifted its stake in Neuronetics by 8.9% in the first quarter. State Street Corp now owns 231,969 shares of the company’s stock worth $438,000 after acquiring an additional 18,953 shares during the period. Spouting Rock Asset Management LLC purchased a new stake in Neuronetics in the first quarter worth $38,000. DAFNA Capital Management LLC lifted its stake in Neuronetics by 25.3% in the first quarter. DAFNA Capital Management LLC now owns 495,772 shares of the company’s stock worth $937,000 after acquiring an additional 100,000 shares during the period. Two Sigma Investments LP raised its holdings in Neuronetics by 155.8% in the first quarter. Two Sigma Investments LP now owns 205,703 shares of the company’s stock worth $389,000 after purchasing an additional 125,272 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in Neuronetics by 473.2% in the first quarter. Two Sigma Advisers LP now owns 132,400 shares of the company’s stock worth $250,000 after purchasing an additional 109,300 shares in the last quarter. 65.20% of the stock is owned by institutional investors.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Read More: 12b-1 Fees

Get a free copy of the Zacks research report on Neuronetics (STIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.